Last reviewed · How we verify

NCT06324890

PET-CT Imaging Features of Meibomian Glands

Status unknown Last updated 22 March 2024
What this trial tests

trial in MGD-Meibomian Gland Dysfunction in 100 participants. Status unknown.

Timeline
31 January 2024
Primary endpoint
31 December 2024
31 December 2024

Quick facts

Lead sponsorZhongnan Hospital
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment100
Start date31 January 2024
Primary completion31 December 2024
Estimated completion31 December 2024
Sites1 location across China

Conditions studied

Sponsor

Zhongnan Hospital

Who can join

Eligibility, any sex, with MGD-Meibomian Gland Dysfunction or Positron-Emission Tomography. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Analysis the results of Dry eye analysis results and PET-CT imaging comprehensively

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Zhongnan Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06324890.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing